Novel approaches to develop Rift Valley fever vaccines.

Sabarish V. Indran, Tetsuro Ikegami

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Rift Valley fever (RVF) is endemic to sub-Saharan Africa, and has spread into Madagascar, Egypt, Saudi Arabia, and Yemen. Rift Valley fever virus (RVFV) of the family Bunyaviridae, genus Phlebovirus causes hemorrhagic fever, neurological disorders or blindness in humans, and high rate abortion and fetal malformation in ruminants. RVFV is classified as a Category A Priority pathogen and overlap select agent by CDC/USDA due to its potential impact on public health and agriculture. There is a gap in the safety and immunogenicity in traditional RVF vaccines; the formalin-inactivated RVFV vaccine TSI-GSD-200 requires three doses for protection, and the live-attenuated Smithburn vaccine has a risk to cause abortion and fetal malformation in pregnant ruminants. In this review, problems of traditional vaccines and the safety and efficacy of recently reported novel RVF candidate vaccines including subunit vaccines, virus vector, and replicons are discussed.

Original languageEnglish (US)
Pages (from-to)131
Number of pages1
JournalFrontiers in cellular and infection microbiology
Volume2
StatePublished - 2012
Externally publishedYes

Fingerprint

Rift Valley Fever
Rift Valley fever virus
Vaccines
Ruminants
Phlebovirus
Bunyaviridae
Yemen
Madagascar
Safety
United States Department of Agriculture
Attenuated Vaccines
Replicon
Subunit Vaccines
Induced Abortion
Saudi Arabia
Africa South of the Sahara
Egypt
Blindness
Centers for Disease Control and Prevention (U.S.)
Nervous System Diseases

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Immunology

Cite this

Novel approaches to develop Rift Valley fever vaccines. / Indran, Sabarish V.; Ikegami, Tetsuro.

In: Frontiers in cellular and infection microbiology, Vol. 2, 2012, p. 131.

Research output: Contribution to journalArticle

@article{d680804e422a48ad969f268f8174ea0c,
title = "Novel approaches to develop Rift Valley fever vaccines.",
abstract = "Rift Valley fever (RVF) is endemic to sub-Saharan Africa, and has spread into Madagascar, Egypt, Saudi Arabia, and Yemen. Rift Valley fever virus (RVFV) of the family Bunyaviridae, genus Phlebovirus causes hemorrhagic fever, neurological disorders or blindness in humans, and high rate abortion and fetal malformation in ruminants. RVFV is classified as a Category A Priority pathogen and overlap select agent by CDC/USDA due to its potential impact on public health and agriculture. There is a gap in the safety and immunogenicity in traditional RVF vaccines; the formalin-inactivated RVFV vaccine TSI-GSD-200 requires three doses for protection, and the live-attenuated Smithburn vaccine has a risk to cause abortion and fetal malformation in pregnant ruminants. In this review, problems of traditional vaccines and the safety and efficacy of recently reported novel RVF candidate vaccines including subunit vaccines, virus vector, and replicons are discussed.",
author = "Indran, {Sabarish V.} and Tetsuro Ikegami",
year = "2012",
language = "English (US)",
volume = "2",
pages = "131",
journal = "Frontiers in cellular and infection microbiology",
issn = "2235-2988",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Novel approaches to develop Rift Valley fever vaccines.

AU - Indran, Sabarish V.

AU - Ikegami, Tetsuro

PY - 2012

Y1 - 2012

N2 - Rift Valley fever (RVF) is endemic to sub-Saharan Africa, and has spread into Madagascar, Egypt, Saudi Arabia, and Yemen. Rift Valley fever virus (RVFV) of the family Bunyaviridae, genus Phlebovirus causes hemorrhagic fever, neurological disorders or blindness in humans, and high rate abortion and fetal malformation in ruminants. RVFV is classified as a Category A Priority pathogen and overlap select agent by CDC/USDA due to its potential impact on public health and agriculture. There is a gap in the safety and immunogenicity in traditional RVF vaccines; the formalin-inactivated RVFV vaccine TSI-GSD-200 requires three doses for protection, and the live-attenuated Smithburn vaccine has a risk to cause abortion and fetal malformation in pregnant ruminants. In this review, problems of traditional vaccines and the safety and efficacy of recently reported novel RVF candidate vaccines including subunit vaccines, virus vector, and replicons are discussed.

AB - Rift Valley fever (RVF) is endemic to sub-Saharan Africa, and has spread into Madagascar, Egypt, Saudi Arabia, and Yemen. Rift Valley fever virus (RVFV) of the family Bunyaviridae, genus Phlebovirus causes hemorrhagic fever, neurological disorders or blindness in humans, and high rate abortion and fetal malformation in ruminants. RVFV is classified as a Category A Priority pathogen and overlap select agent by CDC/USDA due to its potential impact on public health and agriculture. There is a gap in the safety and immunogenicity in traditional RVF vaccines; the formalin-inactivated RVFV vaccine TSI-GSD-200 requires three doses for protection, and the live-attenuated Smithburn vaccine has a risk to cause abortion and fetal malformation in pregnant ruminants. In this review, problems of traditional vaccines and the safety and efficacy of recently reported novel RVF candidate vaccines including subunit vaccines, virus vector, and replicons are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84880261011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880261011&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 131

JO - Frontiers in cellular and infection microbiology

JF - Frontiers in cellular and infection microbiology

SN - 2235-2988

ER -